Brainstorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is 13.19% higher on its value in year-to-date trading and has touched a low of $0.13 and a high of $1.79 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The BCLI stock was last observed hovering at around $0.32 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $0.31, the stock is -2.22% and -10.59% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.15 million and changing -2.98% at the moment leaves the stock -18.71% off its SMA200. BCLI registered -82.34% loss for a year compared to 6-month loss of -10.49%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -7.46% gain in the last 1 month and extending the period to 3 months gives it a -36.50%, and is -8.25% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.72% over the week and 12.69% over the month.
Brainstorm Cell Therapeutics, Inc. (BCLI) has around 29 employees, a market worth around $24.64M and $0.00M in sales. Distance from 52-week low is 130.60% and -82.74% from its 52-week high.
The EPS is expected to grow by 62.50% this year.
Brainstorm Cell Therapeutics, Inc. (BCLI) Top Institutional Holders
53.0 institutions hold shares in Brainstorm Cell Therapeutics, Inc. (BCLI), with institutional investors hold 16.92% of the company’s shares. The shares outstanding are 79.73M, and float is at 72.43M with Short Float at 2.23%. Institutions hold 15.39% of the Float.
The top institutional shareholder in the company is ARMISTICE CAPITAL, LLC with over 7.92 million shares valued at $2.68 million. The investor’s holdings represent 12.2302% of the BCLI Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 1.51 million shares valued at $$0.51 million to account for 2.3334 of the shares outstanding. The other top investors are GEODE CAPITAL MANAGEMENT, LLC which holds 0.48 million shares representing 0.7481% and valued at over $0.16 million, while BLACKROCK INC. holds 0.5969 of the shares totaling 0.39 million with a market value of $0.13 million.
Brainstorm Cell Therapeutics, Inc. (BCLI) Insider Activity
The most recent transaction is an insider sale by Dagher Ibrahim B.,the company’sChief Medical Officer. SEC filings show that Dagher Ibrahim B. sold 63,000 shares of the company’s common stock on Jul 19 ’24 at a price of $0.35 per share for a total of $22069.0. Following the sale, the insider now owns 0.0 shares.
